ES2609636T3 - Composición farmacéutica que comprende un inhibidor no nucleosídico de la transcriptasa inversa - Google Patents

Composición farmacéutica que comprende un inhibidor no nucleosídico de la transcriptasa inversa Download PDF

Info

Publication number
ES2609636T3
ES2609636T3 ES15157348.2T ES15157348T ES2609636T3 ES 2609636 T3 ES2609636 T3 ES 2609636T3 ES 15157348 T ES15157348 T ES 15157348T ES 2609636 T3 ES2609636 T3 ES 2609636T3
Authority
ES
Spain
Prior art keywords
hiv
pharmaceutical composition
alkyl
independently
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15157348.2T
Other languages
English (en)
Spanish (es)
Inventor
Jason Burch
Bernard Cote
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2609636(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Application granted granted Critical
Publication of ES2609636T3 publication Critical patent/ES2609636T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ES15157348.2T 2010-03-30 2011-03-28 Composición farmacéutica que comprende un inhibidor no nucleosídico de la transcriptasa inversa Active ES2609636T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US318824P 2010-03-30
US32157310P 2010-04-07 2010-04-07
US321573P 2010-04-07

Publications (1)

Publication Number Publication Date
ES2609636T3 true ES2609636T3 (es) 2017-04-21

Family

ID=44710363

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15157348.2T Active ES2609636T3 (es) 2010-03-30 2011-03-28 Composición farmacéutica que comprende un inhibidor no nucleosídico de la transcriptasa inversa
ES11761856.1T Active ES2536295T3 (es) 2010-03-30 2011-03-28 Inhibidores no nucleosídicos de la transcriptasa inversa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11761856.1T Active ES2536295T3 (es) 2010-03-30 2011-03-28 Inhibidores no nucleosídicos de la transcriptasa inversa

Country Status (44)

Country Link
US (2) US8486975B2 (2)
EP (2) EP2552902B1 (2)
JP (2) JP5281718B2 (2)
KR (1) KR101421861B1 (2)
CN (1) CN102971308B (2)
AR (1) AR080859A1 (2)
AU (1) AU2011235568B2 (2)
BR (1) BR112012024691B1 (2)
CA (1) CA2794377C (2)
CL (1) CL2012002744A1 (2)
CO (1) CO6630126A2 (2)
CR (1) CR20120503A (2)
CY (3) CY1118774T1 (2)
DK (2) DK2552902T3 (2)
DO (1) DOP2012000256A (2)
EA (1) EA024804B1 (2)
EC (1) ECSP12012201A (2)
ES (2) ES2609636T3 (2)
FI (1) FIC20190021I1 (2)
GE (1) GEP20156368B (2)
HN (1) HN2012002039A (2)
HR (2) HRP20150427T1 (2)
HU (4) HUE025336T2 (2)
IL (2) IL222030A (2)
LT (3) LT2924034T (2)
LU (2) LUC00113I9 (2)
MA (1) MA34170B1 (2)
ME (2) ME02181B (2)
MX (1) MX2012011379A (2)
MY (1) MY163979A (2)
NI (1) NI201200146A (2)
NL (1) NL300980I2 (2)
NO (2) NO2019019I1 (2)
NZ (1) NZ602670A (2)
PE (1) PE20130158A1 (2)
PH (1) PH12012501923A1 (2)
PL (2) PL2552902T3 (2)
PT (2) PT2552902E (2)
RS (2) RS54017B1 (2)
SG (1) SG184347A1 (2)
SI (2) SI2924034T1 (2)
TN (1) TN2012000455A1 (2)
TW (1) TWI458719B (2)
WO (1) WO2011120133A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2924034T1 (sl) * 2010-03-30 2017-05-31 Merck Canada Inc. Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
CA2882947A1 (en) 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
BR112015012843B8 (pt) 2012-12-05 2023-04-25 Merck Sharp & Dohme Método para sintetizar o composto
US20160287568A1 (en) * 2013-11-22 2016-10-06 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
CA2930585A1 (en) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2015153304A1 (en) 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
WO2017095761A1 (en) 2015-12-02 2017-06-08 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
RU2019136678A (ru) 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
JP2021512956A (ja) 2018-02-06 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
EP3823632B1 (en) * 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122571C (en) 2018-12-18 2023-08-01 Merck Sharp & Dohme Corp. Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法
CN116903590A (zh) * 2023-06-06 2023-10-20 延边大学 一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
DE602005017604D1 (de) 2004-04-23 2009-12-24 Hoffmann La Roche Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
AU2006303367A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
SI2924034T1 (sl) * 2010-03-30 2017-05-31 Merck Canada Inc. Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze

Also Published As

Publication number Publication date
DK2924034T3 (en) 2017-02-06
CA2794377A1 (en) 2011-10-06
WO2011120133A1 (en) 2011-10-06
EP2552902B1 (en) 2015-03-11
SI2552902T1 (sl) 2015-10-30
HUS1900021I1 (hu) 2019-05-28
NL300980I1 (nl) 2019-04-24
EA024804B1 (ru) 2016-10-31
KR20120128703A (ko) 2012-11-27
GEP20156368B (en) 2015-09-25
AR080859A1 (es) 2012-05-16
PT2924034T (pt) 2017-01-06
MX2012011379A (es) 2012-11-30
DK2552902T3 (en) 2015-06-15
NZ602670A (en) 2014-09-26
CL2012002744A1 (es) 2012-12-14
CA2794377C (en) 2015-06-16
EP2552902A1 (en) 2013-02-06
PH12012501923A1 (en) 2013-02-04
US20130296382A1 (en) 2013-11-07
HK1209121A1 (en) 2016-03-24
HN2012002039A (es) 2015-08-24
US20110245296A1 (en) 2011-10-06
CY2019026I2 (el) 2020-05-29
HUE031785T2 (en) 2017-08-28
EP2924034A1 (en) 2015-09-30
IL233334A (en) 2015-09-24
HUS1900022I1 (hu) 2019-05-28
EA201290976A1 (ru) 2013-03-29
NL300980I2 (nl) 2021-06-17
NO2019019I1 (no) 2019-04-24
PE20130158A1 (es) 2013-02-28
KR101421861B1 (ko) 2014-07-22
CO6630126A2 (es) 2013-03-01
CN102971308B (zh) 2015-02-04
DOP2012000256A (es) 2012-12-15
CN102971308A (zh) 2013-03-13
CY2019025I2 (el) 2019-11-27
PL2552902T3 (pl) 2015-10-30
HRP20150427T1 (hr) 2015-07-03
RS55505B1 (sr) 2017-05-31
LTC2924034I2 (lt) 2020-10-12
BR112012024691B1 (pt) 2020-11-17
LT2924034T (lt) 2016-12-27
RS54017B1 (sr) 2015-10-30
EP2552902A4 (en) 2013-09-04
LUC00113I9 (2) 2024-06-07
JP5281718B2 (ja) 2013-09-04
CY2019025I1 (el) 2019-11-27
TW201139409A (en) 2011-11-16
ECSP12012201A (es) 2012-10-30
AU2011235568A1 (en) 2012-11-01
PT2552902E (pt) 2015-06-02
LUC00114I2 (2) 2020-07-10
HRP20161680T1 (hr) 2017-01-27
IL233334A0 (en) 2014-09-01
SG184347A1 (en) 2012-11-29
AU2011235568B2 (en) 2013-09-12
SI2924034T1 (sl) 2017-05-31
PL2924034T3 (pl) 2017-07-31
JP5886790B2 (ja) 2016-03-16
ES2536295T3 (es) 2015-05-22
ME02570B (me) 2017-06-20
LTPA2019506I1 (lt) 2019-04-25
HUE025336T2 (en) 2016-03-29
BR112012024691A2 (pt) 2019-07-02
HK1175471A1 (en) 2013-07-05
LUC00113I2 (2) 2024-05-22
IL222030A (en) 2014-07-31
JP2013209405A (ja) 2013-10-10
CR20120503A (es) 2013-01-09
NO2019018I1 (no) 2019-04-24
LUC00114I1 (2) 2019-04-17
EP2924034B1 (en) 2016-11-02
MY163979A (en) 2017-11-15
NI201200146A (es) 2013-03-18
FIC20190021I1 (fi) 2019-04-17
LTC2552902I2 (lt) 2019-12-10
ME02181B (me) 2015-10-20
TWI458719B (zh) 2014-11-01
TN2012000455A1 (en) 2014-01-30
LTPA2019507I1 (lt) 2019-04-25
CY1118774T1 (el) 2017-07-12
JP2013510800A (ja) 2013-03-28
MA34170B1 (fr) 2013-04-03
CY2019026I1 (el) 2020-05-29
US8486975B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
ES2609636T3 (es) Composición farmacéutica que comprende un inhibidor no nucleosídico de la transcriptasa inversa
US10441589B2 (en) Combinations and methods comprising a capsid assembly inhibitor
Xu et al. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets
Jardim et al. Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro
Kovarova et al. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges
JP6280510B2 (ja) 潜伏ｈｉｖウイルスの再活性化におけるインゲノール誘導体
AU2015241247B2 (en) Prodrugs of HIV reverse transcriptase inhibitors
Kumar et al. Pyrazole containing anti-HIV agents: an update
Deval et al. Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase
Gu Newly approved integrase inhibitors for clinical treatment of AIDS
De Clercq The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures
WO2007092326A2 (en) Inhibition of hiv infection through chemoprophylaxis
de Moraes Filho et al. In vivo genotoxicity evaluation of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) alone and in their clinical combinations in Drosophila melanogaster
Nicol et al. HIV PrEP trials: the road to success
US7635690B2 (en) HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
De Clercq Curious discoveries in antiviral drug development: the role of serendipity
Pham et al. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
CN104797259A (zh) 治疗逆转录病毒感染的方法和相关剂量方案
Veel Pilay et al. Nucleoside analogs as potential antiviral agents for dengue virus infections
Coiras et al. Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection
US11191763B2 (en) HIV post-exposure prophylaxis
ES2263449T3 (es) Beta-d-2',3'-didehidro-2',3'-dideoxi-5-fluorocitidina para uso en el tratamiento de infecciones vih.
US20040082552A1 (en) HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine
Strang Toward inhibition of human cytomegalovirus replication with compounds targeting cellular proteins
CA2432287A1 (en) Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor